Lyfgenia Suspension
NDC Package 73554-1111-1
Package Information
Lyfgenia (lovotibeglogene autotemcel) suspension is a cellular therapy administered via intravenous route. This formulation utilizes a suspension delivery system. Marketed by Genetix Biotherapeutics Inc., this product is identified by NDC 73554-1111 and is authorized under FDA application BLA125788.
Identification & Billing
- RxCUI: 2672691 - lovotibeglogene autotemcel 20,000,000 CELLS/ML in 20 ML Injection
- RxCUI: 2672691 - 20 ML lovotibeglogene autotemcel 20000000 CELLS/ML Injection
- RxCUI: 2672691 - lovotibeglogene autotemcel 20,000,000 CELLS/ML per 20 ML Injection
- RxCUI: 2672697 - lyfgenia 20,000,000 CELLS/ML in 20 ML Injection
- RxCUI: 2672697 - 20 ML lovotibeglogene autotemcel 20000000 CELLS/ML Injection [Lyfgenia]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 73554 - Genetix Biotherapeutics Inc.
- 73554-1111 - Lyfgenia
- 73554-1111-1 - 1 mL in 1 BAG
- 73554-1111 - Lyfgenia
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 73554-1111-1 identifies a specific commercial package of 1 ml in 1 bag of Lyfgenia, a cellular therapy labeled by Genetix Biotherapeutics Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This suspension is formulated for intravenous use and contains lovotibeglogene autotemcel as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Genetix Biotherapeutics Inc. on December 08, 2023. The current certification is valid through December 31, 2027.
How is this Genetix Biotherapeutics Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 73554111101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.
